Thomas Trimarchi - 16 May 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: President and CFO
Issuer ticker: BBIO
Reported as of: 16 May 2026
Net transaction value: -$888,419
SEC form: 4
Accepted by SEC: 19 May 2026, 16:30:14 UTC
Prior SEC filing: 20 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Laura Woodhead, Attorney-in-Fact

Key filing fact

Thomas Trimarchi filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 19 May 2026.

Key facts

This page summarizes Thomas Trimarchi's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2026, 16:30.

Change

Previous filing in this sequence was filed on 20 Mar 2026.
Current net transaction value: -$888,419.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002030813 Primary reporting owner

Trimarchi Thomas

Relationship: President and CFO
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Laura Woodhead, Attorney-in-Fact
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Tax liability

Transaction value
Shares: -22,781
Change %: -5.8%
Price: $66.13^*
Shares after: 372,845
Date: 16 May 2026
Ownership: Direct
Footnotes: F1

BBIO transaction

Common Stock

Sale

Transaction value: $677,707
Shares: -10,456
Change %: -2.8%
Price: $64.82
Shares after: 362,389
Date: 18 May 2026
Ownership: Direct
Footnotes: F2, F3

BBIO transaction

Common Stock

Sale

Transaction value: $210,712
Shares: -3,195
Change %: -0.88%
Price: $65.95
Shares after: 359,194
Date: 18 May 2026
Ownership: Direct
Footnotes: F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,193 shares of Common Stock underlying the Reporting Person's RSUs.

Footnote F2

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

Footnote F3

Represents the weighted average sale price of the shares sold from $64.34 to $65.33 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F4

Represents the weighted average sale price of the shares sold from $65.54 to $66.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.